A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies(88 visite) Perani D, Iaccarino L, Lammertsma AA, Windhorst AD, Edison P, Boellaard R, Hansson O, Nordberg A, Jacobs AH, Bottlaender M, Brooks D, Carroll MA, Chalon S, Gee A, Gerhard A, Halldin C, Herholz K, Herth MM, Hinz R, Knudsen GM, Kuhnast B, López-picón F, Moresco RM, Pappata S, Rinne JO, Rodriguez-vieitez E, Santiago-ribeiro MJ, Turkheimer FE, Van Laere K, Varrone A, Vercouillie J, Winkeler A
Alzheimers Dement (ISSN: 1552-5260linking), 2019 Jun 20; N/D: N/D-N/D.
Tipo di articolo: Journal Article,
Impact factor: 14.43, Impact factor a 5 anni: 0
Url: Non disponibile.
Parole chiave: Amyloid, Neuroinflammation, Pet Molecular Imaging, Protheinopathies, Radiotracers,
*** IBB - CNR *** Vita-Salute San Raffaele University, Nuclear Medicine Unit San Raffaele Hospital, Division of Neuroscience San Raffaele Scientific Institute, Milan, Italy., Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands., Division of Brain Sciences, Department of Medicine, Imperial College London, London, UK; Neurology Imaging Unit, Imperial College London, London, UK., Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centres, Amsterdam, The Netherlands., Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden; Memory Clinic, Skane University Hospital, Malmo, Sweden., Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Center for Alzheimer Research, Stockholm, Sweden., European Institute for Molecular Imaging, University of Munster, Munster, Germany; Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. Electronic address: firstname.lastname@example.org.,
Recent studies in neurodegenerative conditions have increasingly highlighted that the same neuropathology can trigger different clinical phenotypes or, vice-versa, that similar phenotypes can be triggered by different neuropathologies. This evidence has called for the adoption of a pathology spectrum-based approach to study neurodegenerative proteinopathies. These conditions share brain deposition of abnormal protein aggregates, leading to aberrant biochemical, metabolic, functional, and structural changes. Positron emission tomography (PET) is a well-recognized and unique tool for the in vivo assessment of brain neuropathology, and novel PET techniques are emerging for the study of specific protein species. Today, key applications of PET range from early research and clinical diagnostic tools to their use in clinical trials for both participants screening and outcome evaluation. This position article critically reviews the role of distinct PET molecular tracers for different neurodegenerative proteinopathies, highlighting their strengths, weaknesses, and opportunities, with special emphasis on methodological challenges and future applications.
12 Records (12 escludendo Abstract e Conferenze). Impact factor totale: 46.483 (46.483 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 30.488 (30.488 escludendo Abstract e Conferenze).